Chronic diseases often need long-acting formulations to improve patient adherence. Here, the authors report a surface-erodible polyketal–tafluprost microparticle formulation that enables extended drug release, prolonged intraocular pressure reduction following a single subconjunctival injection, with good ocular biocompatibility, and enhanced efficacy verified in ocular hypertensive female rats.
- Haiping Zhong
- Tuo Wei
- Shutao Guo